About the causes and therapy of depressive disorders in COVID-19

Abritalin E.Y.

doi:https://doi.org/10.17116/jnevro202112108187

Close metadata

Recommended articles:

The state of mental health of migrant workers and citizens of the Russian Federation: A comparative analysis as illustrated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101

Factors of depression according to actigraphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32

Identification of depression biomarkers: Prospects for use in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):51-55

Depression Anxiety Stress Scale (russian language version). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):103-107

Investigation of the relationship of individual characteristics of the brain bioelectrical activity with levels of mental stress, aggression, anxiety, and depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):108-117

Modern concepts of sleep disturbances associated with mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12

Validation of the Snaith—Hamilton Pleasure Scale to assess anhedonia in patients with unipolar depression In Russia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):110-121

Impact of the COVID-19 epidemic on students’ health. Part II. Features of hemodynamics, vegetative regulation, results of psychological and stress resistance testing among students depending on the COVID-19 presence in their medical history. Russian Journal of Preventive Medicine. 2025;(4):94-101

Gender characteristics of cardiovascular diseases psychosocial risk factors associations with sleep quality in an open urban population. Russian Journal of Preventive Medicine. 2025;(6):67-73

Dysfunctional pelvic pain in women. Russian Journal of Pain. 2025;(2):32-37

Abstract:

Brief information about the causes of depressive disorders in COVID-19 and general strategies of their treatment is presented. According to the biopsychosocial model of the development of mental diseases, depressive disorders in COVID-19 develop due to the toxic effect of the coronavirus on nervous system and other organism systems, possible side-effects of COVID-19 therapy, the psychogenic effect of excessive and inaccurate information about the coronavirus infection and the consequences of its spread, adverse social changes during the pandemic. If infection with the SARS-CoV-2 did not develop, depressive disorders may arise due to psychogenic information and negative social influences. If coronavirus infection is present, depressive disorders can manifest during the acute period of COVID-19 and after recovery from COVID-19. Depressive disorders may occur for the first time in a patient with COVID-19 or infection can aggravate depression that has been in remission. Care should consistently include psychosocial activities, psychocorrection and psychopharmacotherapy. For the prevention of onset of depressive disorders, it is better to implement social-hygienic and psychological-pedagogical measures. Psychotherapy and psychopharmacotherapy become more important in the development of clinically expressed depressive disorders.

Keywords:

depressive disorders

depression

coronavirus infection

COVID-19 pandemic

agomelatine

Authors:

Abritalin E.Y.

Mechnikov North-Western State Medical University;
Almazov National Medical Research Centre;
Kirov Military Medical Academy

Received:

01.07.2021

Accepted:

05.08.2021

Close metadata

References:

Vasileva AV. Evolutional depression model in the time of pandemic. Psychocherapy and psychopharmacotherapy alliance. Obozrenie Psikhiatrii i Meditsinskoy Psikhologii im V.M. Bekhtereva. 2021;1:91-101. (In Russ.). https://doi.org/10.31363/2313-7053-2021-1-91-101
Veltishchev DYu, Lisitsyna TA, Borisova AB. Mental health in populations of different countries during COVID-19 pandemic. Socialnaja i Klinicheskaja Psihiatrija. 2020;30(4):83-86. (In Russ.).
Medvedev VE, Dogotar OA. COVID-19 and mental health: challenges and first conclusions. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2020;12(6):4-10. (In Russ.). https://doi.org/10.14412/2074-2711-2020-6-4-10
Samushia MA, Ragimova AA, Amosova NA, Smolentseva IG, Oynotkinova OSh, Bonkalo TI, Berishvili TZ. Problems of Psycho-Emotional Well-Being of Medical Personnel Working in the Context of the COVID-19 Pandemic. Vestnik Rossiyskoy Akademii Meditsinskikh Nauk. 2020;75(5S):426-433. (In Russ.). https://doi.org/10.15690/vramn1426
Shepeleva II, Chernysheva AA, Kiryanova EM, Salnikova LI, Gurina OI. The nervous system damages and psychological and psychiatric complications on the COVID-19 pandemic. Socialnaja i Klinicheskaja Psihiatrija. 2020;30(4):76-82. (In Russ.).
Shmukler AB. Psychiatric and neurological disorders in patients with new corona virus infection as multidisciplinary problem. Socialnaja i Klinicheskaja Psihiatrija. 2021;31(1):65-73. (In Russ.).
Bhatia MS, Goyal S, Singh A, Daral A. COVID-19 Pandemicinduced Panic Disorder. The Primary Care Companion for CNS Disorders. 2020;22(3): 20102626. https://doi.org/10.4088/PCC.20l02626
Bueno-Notivol J, Gracia-García P, Olaya B, Lasheras I, López-Antón R, Santabárbara J. Prevalence of depression during the COVID-19 outbreak: A meta-analysis of community-based studies. International Journal of Clinical and Health Psychology. 2021;21(1):100196. https://doi.org/10.1016/j.ijchp.2020.07.007
Yesilkaya UH, Balcioglu YH, Sahin S. Reissuing the sigma receptors for SARS-CoV-2. Journal of Clinical Neuroscience. 2020;80:72-73. https://doi.org/10.1016/j.jocn.2020.08.014
Petrova NN, Morozov PV, Markin AV, Bekker RA, Bykov YuV. The COVID-19 pandemic: challenges of our times, with discussion on the latest data regarding an issue of rational psychopharmacotherapy choices in patients with SARS-CoV-2 infection. Psihiatrija i Psihofarmakoterapija. 2020;22(6):8-24. (In Russ.).
Neznanov NG, Samushiya MA, Mazo GE, Titova VV, Vasil’yeva AV, Lutova NB, Karavayeva TA, Smolentseva IG, Amosova NA, Ragimova AA, Gusakova YeV, Konchugova TV, Ivanova II, Petrova MS, Zaytsev OS, Chorbinskaya SA, Otmakhov AP, Kryzhanovskiy SM, Mironova NV, Berishvili TZ. Algoritmy diagnostiki i terapii psikhicheskikh rasstroystv, registriruyemykh v period pandemii COVID-19: uchebnoye posobiye. M.: Tsentral’naya gosudarstvennaya meditsinskaya akademiya Upravleniya delami Prezidenta Rossiyskoy Federatsii; 2021. (In Russ.).
Investing in treatment for depression and anxiety leads to fourfold return. Who. Accessed June 18, 2021. https://www.who.int/news/item/13-04-2016-investing-in-treatment-for-depression-and-anxiety-leads-to-fourfold-return
Key facts. Depression. Who. Accessed June 18, 2021. https://www.who.int/news-room/fact-sheets/detail/depression
Bueno-Notivol J, Gracia-García P, Olaya B, Lasheras I, López-Antón R, Santabárbara J. Prevalence of depression during the COVID-19 outbreak: A meta-analysis of community-based studies. International Journal of Clinical and Health Psychology. 2021;21(1):100196. https://doi.org/10.1016/j.ijchp.2020.07.007
Deng J, Zhou F, Hou W, Silver Z, Wong CY, Chang O, Huang E, Zuo QK. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Annals of the New York Academy of Sciences. 2021; 1486(1):90-111. https://doi.org/10.1111/nyas.14506
Talevi D, Socci V, Carai M, Carnaghi G, Faleri S, Trebbi E, Bernardo AD, Capelli F, Pacitti F. Mental health outcomes of the CoViD-19 pandemic. Rivista di Psichiatria. 2020;55(3):137-144. https://doi.org/10.1708/3382.33569
Reger MA, Stanley IH, Joiner TE. Suicide Mortality and Coronavirus Disease 2019-A Perfect Storm? JAMA Psychiatry. 2020;77(11):1093-1094. https://doi.org/10.1001/jamapsychiatry.2020.1060
Rothberg MB, Martinez KA. Influenza Management via Direct to Consumer Telemedicine: an Observational Study. Journal of General Internal Medicine. 2020;35:3111-3113. https://doi.org/10.1007/s11606-020-05640-5
Zhovnerchuk EV, Zhovnerchuk IY, Abritalin EY, Fedorov NV. Telepsychiatry as a new system of mental health care by using modern technologies. Psihicheskoe Zdorove. 2016;11(126):15-21. (In Russ.).
Medvedev VE. Anxiety and depression in COVID-19: treatment options. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2021;13(2):111-116. (In Russ.). https://doi.org/10.14412/2074-2711-2021-2-111-116
Mosolov SN, Malin DI, Tsukarzi EE, Kostyukova EG. Drug Therapy for Patients with Mental Disorders Who Have a Coronavirus Infection (COVID-19). Sovremennaja Terapija Psihicheskih Rasstrojstv. 2020;2:34-39. (In Russ.). https://doi.org/10.21265/PSYPH.2020.18.69.001
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Socialnaja i Klinicheskaja Psihiatrija. 2018;28(4):61-69. (In Russ.).
Tsygankov BD, Yaltonskaya AV, Filippskih SV. Valdoxan (agomelatin) in the therapy of severe and moderate depressions of the non-psychotic level (results of the observational research time (vremya)). Obozrenie Psikhiatrii i Meditsinskoy Psikhologii im V.M. Bekhtereva. 2011;1:37-40. (In Russ.).
Bykov YuV, Bekker RA. Agomelatine: extended indications for its use in psychiatry, neurology and substance abuse medicine. Psihiatrija i Psihofarmakoterapija. 2018;20(3-4):4-18. (In Russ.).
Medvedev VE. Treatment of mild and moderate Major Depressive Disorder with Valdoxane (agomelatine) in patients with cardiovascular disorders: results of the National Observational Multicenter Study PULSE Psihiatrija i Psihofarmakoterapija. 2014;16(5):30-35. (In Russ.).
Yakhno NN, Voznesenskaya TG. Efficacy and tolerance of agomelatin (valdoxan) in the treatment of mild and moderate depression in neurologic practice (the results of russian multicenter research «Camertone»). Nevrologicheskij Zhurnal. 2012;1:43-49. (In Russ.).
Freiesleben SD, Furczyk KJ. A systematic review of agomelatineinduced liver injury. Journal of Molecular Psychiatry. 2015;3(1):4. https://doi.org/10.1186/s40303-015-0011-7
Perlemuter G, Cacoub P, Valla D, Guyader D, Saba B, Batailler C, Moore K. Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients. CNS Drugs. 2016;30(9):877-888. https://doi.org/10.1007/s40263-016-0351-6
Volel BA. Safety and efficacy of agomelatine in the treatment of anxiety and depressive disorders in clinical practice (based on OCTAVA protocol). Psihiatrija i Psihofarmakoterapija. 2015;17(2):9-14. (In Russ.).
Billioti de Gage S, Collin C, Le Tri T, Pariente A, Dray-Spira R, Zureik M. Hepatotoxicity of agomelatine and other antidepressants versus selective serotonin reuptake inhibitors. European Neuropsychopharmacology. 2017; 27(4):844. https://doi.org/10.1016/S0924-977X(17)31518-3